DeviceTalks Boston is a Wrap – Gauging the impact of Big Pharma, AI, PE and other forces on Medtech

In our closing session of DeviceTalks Boston, Chris Newmarker, executive editor of life sciences, and Tom Salemi, Editorial Director of DeviceTalks, sit down with two leaders in the field to break down the event and highlight some of the changes coming Medtech’s ways. Joe Mullings, CEO of the Mullings Group, and former J&J Medtech leader Peter Stebbins, now executive chairman of Nurami Medical, cover a broad range of topics on how will Big Pharma, AI, data, private equity and other external forces will impact the medical device industry. Are we going to see more roll ups from PE? Will a new threat emerge to thwart Medtech’s connected care plan. Also, what were the takeaways from the discussions of the conference. Give a listen. Thanks to everyone who made DeviceTalks Boston so special! Thanks for listening to the DeviceTalks Weekly podcast. Subscribe on any podcast application.